Pregabalin significantly improved pain and sleep quality, without clinically meaningful differences between diabetes types, reported by a recent study published in Current Medical Research and Opinion. 

B Parsons et al. conducted a study to differentiate between the efficacy and safety of pregabalin for painful diabetic peripheral neuropathy (pDPN) in patients with type 1 (T1DM) or 2 diabetes mellitus (T2DM). Pooled data from 10 randomised clinical trials (pregabalin-treated T1DM and T2DM subjects with pDPN) were examined for change from the baseline (CFB) scores (pain and sleep disturbance). For this purpose, mixed model repeated measures (MMRM) were used through Week 12, and last observation carried forward (LOCF). The adverse events (AEs) were recorded. The pregabalin-treated (T1DM 156 [8.7%]; T2DM 1632 [91.3%]) and placebo subjects (T1DM 92 [9.6%]; T2DM 868 [90.4%]) had comparable baseline demographic characteristics between treatment groups in the same diabetes type. T2DM (vs T1DM) subjects were ∼10 years older. The mean ± SD baseline pain (T1DM: 6.2 ± 1.4 and 6.5 ± 1.6; T2DM: 6.5 ± 1.5 and 6.4 ± 1.5) and sleep scores (T1DM: 5.2 ± 2.4 and 5.2 ± 2.7; T2DM: 5.3 ± 2.5 and 5.1 ± 2.5) were comparable with pregabalin and placebo. The mean CFB treatment differences (pregabalin minus placebo) were significantly dissimilar for pain and sleep with either of the diabetes types when using MMRM. The pregabalin's odds ratios (ORs) of attaining 30% pain reduction were similar with T2DM (OR, 1.91, 95% CI [1.61, 2.27]) and T1DM (2.01 [1.18, 3.44]) with LOCF. Pregabalin's ORs of 30% improvement in sleep quality was 1.81 with T1DM and 2.01 (1.69, 2.39) with T2DM. AEs followed the known safety profile of pregabalin.